Latest News in the pharma Industry
Top Stories
Allergan confirms generic Rytary patent challenge
21 Sep 2015
Allergan's ANDA product is a generic version of Impax Laboratories' Rytary.
Read more
Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola
21 Sep 2015
HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.
Read more
Selvita establishes its first operations in the US
21 Sep 2015
The largest drug discovery company in Central and Eastern Europe opens offices in Cambridge, MA and San Bruno, CA.
Read more
Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
18 Sep 2015
Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company's Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of...
Read more
CPhI expert warns without urgent regulatory change improving quality is a fool’s game
18 Sep 2015
Girish Malhotra believes the pharmaceutical industry should be allowed to commercialise process improvements without regulatory re-approval.
Read more
Piramal encourages pharma to embrace green chemistry ahead of CPhI
18 Sep 2015
Processes improvements for original patented products need to be considered, as do improvements beyond even DMF and ANDA submission.
Read more
The new age of regenerative medicine: why stem cell therapy?
18 Sep 2015
Frost & Sullivan webinar reveals stem cell therapy pipeline and treatments innovating regenerative medicine.
Read more
Victoza (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial
17 Sep 2015
Findings from a head-to-head trial comparing Victoza (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 ...
Read more
CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP GT technology
17 Sep 2015
Agreement enables fully scalable, industrial lentivirus vector production
Read more
Impax receives FDA approval for generic version of Mestinon Timespan Tablets, 180 mg
17 Sep 2015
First generic product approved from Hayward manufacturing facility following recent resolution of Warning Letter
Read more
Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy
17 Sep 2015
Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, Januvia (sitagliptin), at reducing patients’ A1C levels from baseline, with similar A1C reductions achieved in both groups.
Read more
Using proteomics to understand how genetic mutations rewire cancer cells
17 Sep 2015
Scientific publications highlight studies using data from Thermo Scientific Orbitrap mass spectrometry and next-generation sequencing to discover how cancer attacks the protein networks controlling human cells
Read more